Faculty profile

Josee Ethier

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Toronto

Josee Ethier

Associate Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
23 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,872

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Concordance between circulating tumor DNA and tissue biopsy in patients with newly diagnosed recurrent breast cancer.
Journal of Clinical Oncology · 2026
First line maintenance treatment patterns and clinical outcomes by BRCA status in advanced ovarian cancer patients in Canada
Gynecologic Oncology · 2026 · senior author
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.
Current oncology (Toronto, Ont.) · 2026

All 54 publications

54 publications.

Concordance between circulating tumor DNA and tissue biopsy in patients with newly diagnosed recurrent breast cancer.

Ana Elisa Lohmann, Marguerite Ennis, Zachary William Neil Veitch, Christine Brezden-Masley, Katarzyna Joanna Jerzak, Samuel Martel, Julie Lemieux, José Luiz Guimarães, David W. Cescon, Kathie Baer, Josée-Lyne Ethier, Brooke Wilson, Derek Dustin, Sara V. Soldera, Pamela Jean Goodwin

Journal of Clinical Oncology20261 citations

DOI: 10.1200/jco.2026.44.16_suppl.1031

First line maintenance treatment patterns and clinical outcomes by BRCA status in advanced ovarian cancer patients in Canada

Sydney George, Maud Marques, Diana Granados, Simran Shokar, Karen Gambaro, Josée-Lyne Ethier

Gynecologic Oncology2026Senior author

DOI: 10.1016/j.ygyno.2026.01.633

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Ma K, Tessier-Cloutier B, Altman AD, Carey MS, Ethier JL, Lau S, Lee CH, Hopkins L, Kieser K, Kumar A, Leung SOA, Nguyen JMV, MacKay H, McGee J, Salman L, Salvador S, Sluce C, Tatar L, Tone AA, Tinker A, Tremblay E, Veneziani AC, Vicus D, Welch S, Windsor Harker S, Brodeur MN

Current oncology (Toronto, Ont.)2026Open Access

DOI: 10.3390/curroncol33060330 PMID: 42346230

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Vergote I, Cibula D, Powell M, Laenen A, Nieuwenhuysen EV, Topuz S, González-Martín A, Fujiwara K, Safina S, Bagaméri A, Oliver M, Lee JY, Salutari V, Korach J, Lu CH, Mądry R, Vulsteke C, Colombo N, Sehouli J, Klat J, Ruiz EY, Gilbert L, Pautier P, Pardo B, Kridelka F, Wei J, Toker S, Yamada K, Coleman RL, ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators

The Lancet. Oncology2026

DOI: 10.1016/s1470-2045(26)00223-8 PMID: 42705254

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI

Journal of Clinical Oncology202575 citationsOpen Access

DOI: 10.1200/jco-24-01326

Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison

Josée-Lyne Ethier, Cal S. Shephard, Diana P. Granados, Nikkita Dutta, Rana A. Qadeer, Saima Ahmad, Ellen Kasireddy, Mir‐Masoud Pourrahmat, Mir Sohail Fazeli

Gynecologic Oncology20251 citationsFirst authorOpen Access

DOI: 10.1016/j.ygyno.2025.03.022 PMID: 40132433

Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: A systematic literature review and indirect treatment comparison

Nikkita Dutta, Diana Granados, Josée-Lyne Ethier, Cal S. Shephard, Rana A. Qadeer, Saima Ahmad, Ellen Kasireddy, Mir‐Masoud Pourrahmat, Mir Sohail Fazeli

Gynecologic Oncology2025

DOI: 10.1016/j.ygyno.2025.04.300

Healthcare resource use in the management of advanced epithelial ovarian cancer in Canada.

Kimberly Guinan, Laurie Demers-Rozon, Yoann Brassard, Nancy Paul Roc, Hélène Hall, Nathan F. Schachter, Anna V. Tinker, Josée-Lyne Ethier, Shannon Salvador, Stéphane Barakat, Francesc Sorio, Jean Lachaîne

Journal of Clinical Oncology2025

DOI: 10.1200/jco.2025.43.16_suppl.e17565

Increasing Diversity In Gynaecological Cancer Trials: The GCIG Statement From The Barcelona Meeting

Jalid Sehouli, Amit M. Oza, Jennifer O’Donnell, Katherine Bennett, Josée-Lyne Ethier, Philipp Harter, Ting‐Chang Chang, Sharon A. O’Toole, Christianne A. R. Lok, Ainhoa Madariaga, Jose Alejandro Rauh‐Hain, David S.P. Tan, Judith Michels, Ora Solange Rosengarten, Elisa Piovano, Uma Mukherjee, Sara A. Nasser, Jennifer M. Croke, Franziska Geissler, Michael A. Bookman

International Journal of Gynecological Cancer2025Open Access

DOI: 10.1016/j.ijgc.2024.101566

Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial.

Yin C, Ethier JL, Carey MS, Tu D, Zheng X

Current oncology (Toronto, Ont.)2025Open Access

DOI: 10.3390/curroncol32070390 PMID: 40710200

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Josee Ethier

Research

Latest papers

Concordance between circulating tumor DNA and tissue biopsy in patients with newly diagnosed recurrent breast cancer.

First line maintenance treatment patterns and clinical outcomes by BRCA status in advanced ovarian cancer patients in Canada

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison

Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: A systematic literature review and indirect treatment comparison

Healthcare resource use in the management of advanced epithelial ovarian cancer in Canada.

Increasing Diversity In Gynaecological Cancer Trials: The GCIG Statement From The Barcelona Meeting

Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial.

Frequent collaborators

Josee-Lyne Ethier

Eitan Amir

Amit Oza

Stephanie Lheureux

Neesha Dhani

Amirrtha Srikanthan

Danielle Desautels

Lisa Wang

Lucy Gilbert

Tracy Stockley

Jacob McGee

David Cescon

Stephen Welch

Anna Tinker

Pamela Ohashi

Laurie Elit

Holger Hirte

Xiaomei Yao

Christine Maheu

Janet Jull

Sonal Gandhi

Helen MacKay

Danielle Vicus

Prakesh Shah

Laura Hopkins

Josee Ethier

Research

Latest papers

Concordance between circulating tumor DNA and tissue biopsy in patients with newly diagnosed recurrent breast cancer.

First line maintenance treatment patterns and clinical outcomes by BRCA status in advanced ovarian cancer patients in Canada

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor &#x3b1; Testing in Ovarian Cancer.

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison

Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: A systematic literature review and indirect treatment comparison

Healthcare resource use in the management of advanced epithelial ovarian cancer in Canada.

Increasing Diversity In Gynaecological Cancer Trials: The GCIG Statement From The Barcelona Meeting

Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial.

Frequent collaborators

Josee-Lyne Ethier

Eitan Amir

Amit Oza

Stephanie Lheureux

Neesha Dhani

Amirrtha Srikanthan

Danielle Desautels

Lisa Wang

Lucy Gilbert

Tracy Stockley

Jacob McGee

David Cescon

Stephen Welch

Anna Tinker

Pamela Ohashi

Laurie Elit

Holger Hirte

Xiaomei Yao

Christine Maheu

Janet Jull

Sonal Gandhi

Helen MacKay

Danielle Vicus

Prakesh Shah

Laura Hopkins

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.